{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:44:20Z","timestamp":1785897860811,"version":"3.56.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Cytopathology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jasc.2022.04.001","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T12:19:21Z","timestamp":1649247561000},"page":"183-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cytomorphologic and immunophenotypical analysis of SMARCA4 (BRG1)-deficient non-small cell lung carcinoma"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5116-7204","authenticated-orcid":false,"given":"Oluwaseun B.","family":"Ogunbona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0760-3950","authenticated-orcid":false,"given":"Xiaoqi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L.","family":"Hornick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0409-2374","authenticated-orcid":false,"given":"Daniel J.","family":"Lubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5093-785X","authenticated-orcid":false,"given":"Qun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3812-4098","authenticated-orcid":false,"given":"Michelle D.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong M.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0224-3167","authenticated-orcid":false,"given":"Qiuying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jasc.2022.04.001_bib1","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1038\/s41467-020-19402-8","article-title":"Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients","volume":"11","author":"Fernando","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jasc.2022.04.001_bib2","doi-asserted-by":"crossref","first-page":"a026930","DOI":"10.1101\/cshperspect.a026930","article-title":"The many roles of BAF (mSWI\/SNF) and PBAF complexes in cancer","volume":"6","author":"Hodges","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jasc.2022.04.001_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5858\/arpa.2019-0633-OA","article-title":"SMARCA4\/BRG1-deficient non-small cell lung carcinomas: a case series and review of the literature","volume":"145","author":"Nambirajan","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jasc.2022.04.001_bib4","article-title":"Thoracic SMARCA4-deficient undifferentiated tumour","volume":"vol. 5","author":"Yoshida","year":"2021"},{"key":"10.1016\/j.jasc.2022.04.001_bib5","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-20-1825","article-title":"The genomic landscape of SMARCA4\u00a0alterations and associations with outcomes in patients with lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jasc.2022.04.001_bib6","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jtho.2020.01.002","article-title":"Clinicopathologic characteristics of BRG1-deficient NSCLC","volume":"15","author":"Dagogo-Jack","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jasc.2022.04.001_bib7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00428-017-2148-5","article-title":"SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1","volume":"471","author":"Agaimy","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jasc.2022.04.001_bib8","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/modpathol.2017.61","article-title":"SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior","volume":"30","author":"Sauter","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jasc.2022.04.001_bib9","doi-asserted-by":"crossref","first-page":"14098","DOI":"10.1038\/ncomms14098","article-title":"SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers","volume":"8","author":"Tagal","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jasc.2022.04.001_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000510323","article-title":"Cytology of SMARCA4-deficient thoracic neoplasms: comparative analysis of SMARCA4-deficient non-small cell lung carcinomas and SMARCA4-deficient thoracic sarcomas","author":"Nambirajan","year":"2021","journal-title":"Acta Cytol"},{"key":"10.1016\/j.jasc.2022.04.001_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jasc.2020.08.002","article-title":"Review of SMARCA4 (BRG1)-deficient carcinomas following a malignant pleural effusion specimen confounded by reduced claudin-4 expression","volume":"10","author":"Early","year":"2021","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.jasc.2022.04.001_bib12","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000493335","article-title":"Cytologic features of SMARCA4-deficient thoracic sarcoma: a case report and comparison with other SWI\/SNF complex-deficient tumors","volume":"62","author":"Matsushita","year":"2018","journal-title":"Acta Cytol"},{"key":"10.1016\/j.jasc.2022.04.001_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2019.10.009","article-title":"Non-small cell lung cancer with loss of expression of the SWI\/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden","volume":"138","author":"Naito","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jasc.2022.04.001_bib14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.anndiagpath.2016.10.006","article-title":"SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens","volume":"26","author":"Herpel","year":"2017","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.jasc.2022.04.001_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/PAS.0000000000001188","article-title":"SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses","volume":"43","author":"Perret","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jasc.2022.04.001_bib16","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/ng.3399","article-title":"SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas","volume":"47","author":"Le Loarer","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jasc.2022.04.001_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jtho.2019.10.023","article-title":"SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas","volume":"15","author":"Rekhtman","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jasc.2022.04.001_bib18","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/1759-7714.13070","article-title":"Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: a case report","volume":"10","author":"Naito","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jasc.2022.04.001_bib19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s13691-021-00472-4","article-title":"Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor","volume":"10","author":"Tanaka","year":"2021","journal-title":"Int Cancer Conf J"},{"key":"10.1016\/j.jasc.2022.04.001_bib20","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jasc.2022.04.001_bib21","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jasc.2022.04.001_bib22","doi-asserted-by":"crossref","first-page":"10155","DOI":"10.1021\/acs.jmedchem.8b01318","article-title":"Discovery of orally active inhibitors of Brahma homolog (BRM)\/SMARCA2 ATPase activity for the treatment of Brahma related gene 1 (BRG1)\/SMARCA4-mutant cancers","volume":"61","author":"Papillon","year":"2018","journal-title":"J Med Chem"}],"container-title":["Journal of the American Society of Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213294522000394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213294522000394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T06:47:14Z","timestamp":1761979634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213294522000394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2213294522000394"],"URL":"https:\/\/doi.org\/10.1016\/j.jasc.2022.04.001","relation":{},"ISSN":["2213-2945"],"issn-type":[{"value":"2213-2945","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytomorphologic and immunophenotypical analysis of SMARCA4 (BRG1)-deficient non-small cell lung carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Cytopathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jasc.2022.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Society of Cytopathology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}